Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus

Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus OBSERVATION ONLINE FIRST Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus A Case Series of 9 Patients Setsuko Matsukura, MD, PhD; Sandra R. Knowles, BScPhm; Scott Walsh, MD, PhD; Neil H. Shear, MD Background: There is increasing evidence that a single the mean dosage of prednisone was observed at 3 and 6 cycle of rituximab (375 mg per square meter of body sur- months. Relapses were observed in 4 patients between 5 face area once weekly for 4 weeks) is efficacious in pa- and 13 months after rituximab treatment; these patients tients with severe pemphigus. The approved protocol in completed a second cycle of rituximab. There were no rheumatoid arthritis is1gon days 1 and 15. We report serious adverse effects observed during the follow-up herein on the efficacy and safety of this latter protocol period. for rituximab in 9 patients with pemphigus. Conclusions: A single cycle of rituximab,1gon days 1 Observations: Nine patients with recalcitrant pem- and 15, is an effective treatment for pemphigus. Further phigus were treated with prednisone, immunosuppres- studies are needed to determine the efficacy and safety sive agents, and/or intravenous immunoglobulin. Ritux- of repeated treatment courses in patients who experi- imab, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus

Loading next page...
 
/lp/american-medical-association/effect-of-a-single-cycle-alternative-dosing-regimen-for-rituximab-for-EenkkJs9HC
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archdermatol.2011.3320
pmid
22351790
Publisher site
See Article on Publisher Site

Abstract

OBSERVATION ONLINE FIRST Effect of a Single-Cycle Alternative Dosing Regimen for Rituximab for Recalcitrant Pemphigus A Case Series of 9 Patients Setsuko Matsukura, MD, PhD; Sandra R. Knowles, BScPhm; Scott Walsh, MD, PhD; Neil H. Shear, MD Background: There is increasing evidence that a single the mean dosage of prednisone was observed at 3 and 6 cycle of rituximab (375 mg per square meter of body sur- months. Relapses were observed in 4 patients between 5 face area once weekly for 4 weeks) is efficacious in pa- and 13 months after rituximab treatment; these patients tients with severe pemphigus. The approved protocol in completed a second cycle of rituximab. There were no rheumatoid arthritis is1gon days 1 and 15. We report serious adverse effects observed during the follow-up herein on the efficacy and safety of this latter protocol period. for rituximab in 9 patients with pemphigus. Conclusions: A single cycle of rituximab,1gon days 1 Observations: Nine patients with recalcitrant pem- and 15, is an effective treatment for pemphigus. Further phigus were treated with prednisone, immunosuppres- studies are needed to determine the efficacy and safety sive agents, and/or intravenous immunoglobulin. Ritux- of repeated treatment courses in patients who experi- imab,

Journal

JAMA DermatologyAmerican Medical Association

Published: Jun 1, 2012

References